海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
30件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A comparison study of TRx0237 and placebo in patients with mild to moderate Alzheimer's Disease
- Alzheimer’s Disease MedDRA version: 18.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Bulgaria, Canada, Croatia, Germany, Italy, Korea, Republic of, Malaysia, Poland, Romania, Russian Federation, Singapore, Spain, Taiwan, United Kingdom, United States
- 2012-11-02
Authorised
- To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.
- Relapsed and/or Refractory Multiple Myeloma MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Singapore, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, United States
- 2012-04-24
Authorised
- A Study of Gantenerumab in Patients with Mild Alzheimer Disease
- MILD ALZHEIMER’S DISEASE MedDRA version: 18.1 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Finland, France, Germany, Guatemala, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States
- 2013-12-10
Authorised
- A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease
- Prodromal Alzheimer’s Disease MedDRA version: 20.0 Level: LLT Classification code 10066571 Term: Progression of Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Turkey, United Kingdom
- 2010-08-27
Authorised
- An open label, prospective, multicenter study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT595 as replacement therapy in patients with primary immunodeficiency disease (PID)
- Replacement therapy in patients with primary immunodeficiency disease (PID) MedDRA version: 20.0 Level: PT Classification code 10064859 Term: Primary immunodeficiency syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Germany, Russian Federation, Spain, United Kingdom, United States
- 2016-05-18
Authorised
- 221AD301 Phase 3 Study of Aducanumab in Early Alzheimer's Disease
- Early Alzheimer's Disease MedDRA version: 18.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Portugal, Spain, Taiwan, United Kingdom, United States
- 2015-06-03
Authorised
- 221AD302 Phase 3 Study of Aducanumab in Early Alzheimer's Disease
- Early Alzheimer's Disease MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Poland, Portugal, Spain, Sweden, Taiwan, United Kingdom, United States
- 2015-05-18
Authorised
- A Study of LY3314814 in Participants With Mild Alzheimer's Disease Dementia (Daybreak)
- Alzheimer’s Disease with Dementia MedDRA version: 19.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Canada, China, Czech Republic, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Taiwan, United Kingdom, United States
- 2016-04-25
Authorised
- A clinical study to investigate the efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the prevention of Acute Graft-versus-Host-Disease in adult and pediatric patients after allogeneic hematopoietic stem cell transplant
- Prevention of Acute Graft-versus-Host Disease (aGvHD) after allogeneic hematopoietic stem cell transplant MedDRA version: 20.0 Level: LLT Classification code 10068908 Term: AGVHD System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
- Belgium, Canada, France, Germany, Italy, Spain, Turkey, United Kingdom, United States
- 2017-12-01
Authorised
- A clinical study to investigate the efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the prevention of Acute Graft-versus-Host-Disease in adult and pediatric patients after allogeneic hematopoietic stem cell transplant
- Prevention of Acute Graft-versus-Host Disease (aGvHD) after allogeneic hematopoietic stem cell transplant MedDRA version: 20.0 Level: LLT Classification code 10068908 Term: AGVHD System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
- Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Italy, Poland, Portugal, Spain, Turkey, United Kingdom, United States
- 2017-11-28
